New Partnership Aims to Improve Genomic Variant Interpretation

Agilent and Genomenon team up to bring users more effective software and search tools for making a genetic diagnosis.

On June 7, genomic health IT company Genomenon announced it has partnered with analytical instrument manufacturer Agilent to give diagnostic labs a more effective tool for genomic variant interpretation. The partnership, which includes two phases, will involve integrating Genomenon’s Mastermind® Genomic Search Engine into the latest version of Agilent’s Alissa Interpret genomic data analysis and variant interpretation software. Each phase of the partnership will bring different capabilities to users of the cloud-based software:

Phase 1: Will allow users to filter and review variants based on the number of published articles those variants are described in, then easily view that evidence in Mastermind
Phase 2: Planned to begin in 2022, this phase will bring users the ability to evaluate and review literature search results in more detail, directly in the application

“We are excited to partner with Agilent, an organization that is committed to making genomic analysis for clinical decision support faster, easier, and more effective,” said Mike Klein, CEO of Genomenon, in a statement. “With this deeper integration, users of Agilent’s Alissa Interpret will experience an optimized workflow by being able to quickly view the evidence needed to make a genetic diagnosis.”¹

Other recently announced partnerships and collaborations from last week also touched on genomics:

June 6: Single-cell sequencing solutions provider Parse Biosciences announced a partnership with Molecular Diagnostics Korea that aims to bring several of its single cell genomics research-related products to South Korea²

June 2: Labcorp announced that it is now offering a new testing program, sponsored by Eli Lilly and Company, to help those with advanced non-small cell lung cancer (NSCLC) and their doctors make better decisions regarding care management and treatment. The program will use Labcorp’s OmniSeq INSIGHT^SM pan-cancer, tissue-based sequencing test.³

June 2: Healthcare company GRAIL, LLC, announced it will be collaborating with AstraZeneca on the development of companion diagnostic tests in order to identify those with early-stage, high-risk cancer. Over the next several years, the two companies will be involved in “numerous studies across multiple indications,” according to a statement.⁴

June 1: GE Healthcare, the healthcare business of GE, and Ireland-based healthcare tech company Medtronic announced they will be partnering to offer global access to personalized care through their patient monitoring solutions. The two companies received FDA 510(k) clearance and CE Mark approval on the integration of Medtronic’s INVOS™ regional oximetry and Microstream™ capnography technologies on GE’s CARESCAPE precision monitoring platform, which aim to improve patient safety and outcomes.⁵

New Partnership Aims to Improve Genomic Variant Interpretation

References:

Log In